Breast oncologists are intimately familiar with managing treatment-related adverse events of endocrine, cytotoxic and targeted therapies, but the approval of immune-checkpoint inhibitors (ICIs) for metastatic triple-negative breast cancer (TNBC) poses new challenges. Herein, we discuss the safety of ICIs in metastatic TNBC, with an emphasis on immune-related adverse events.
This is a preview of subscription content, access via your institution
Relevant articles
Open Access articles citing this article.
-
Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling
Nature Communications Open Access 01 August 2022
-
Immunotherapy toxicity: identification and management
Breast Cancer Research and Treatment Open Access 11 January 2022
-
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
npj Breast Cancer Open Access 08 October 2019
Access options
Access Nature and 54 other Nature Portfolio journals
Get Nature+, our best-value online-access subscription
$29.99 / 30 days
cancel any time
Subscribe to this journal
Receive 12 print issues and online access
$209.00 per year
only $17.42 per issue
Buy this article
- Purchase on SpringerLink
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
References
Schmid, P. et al. Atezolizumab and nab-paclitaxel in advanced triple-negative breast cancer. N. Engl. J. Med. 379, 2108–2121 (2018).
Adams, S. et al. Atezolizumab plus nab-paclitaxel in the treatment of metastatic triple-negative breast cancer with 2-year survival follow-up: a phase 1b clinical trial. JAMA Oncol. 5, 334–342 (2019).
Emens, L. A. et al. Long-term clinical outcomes and biomarker analyses of atezolizumab therapy for patients with metastatic triple-negative breast cancer: a phase 1 study. JAMA Oncol. 5, 74–82 (2019).
Adams, S. et al. Pembrolizumab monotherapy for previously treated metastatic triple-negative breast cancer: cohort A of the phase 2 KEYNOTE-086 study. Ann. Oncol. 30, 397–404 (2019).
Adams, S. et al. Pembrolizumab monotherapy for previously untreated, PD-L1-positive, metastatic triple-negative breast cancer: cohort B of the phase 2 KEYNOTE-086 study. Ann Oncol. 30, 405–411 (2019).
Nanda, R. et al. Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study. J. Clin. Oncol. 34, 2460–2467 (2016).
Dirix, L. Y. et al. Avelumab, an anti-PD-L1 antibody, in patients with locally advanced or metastatic breast cancer: a phase 1b JAVELIN solid tumor study. Breast Cancer Res. Treat. 167, 671–686 (2018).
Santa-Maria, C. A. et al. A pilot study of durvalumab and tremelimumab and immunogenomic dynamics in metastatic breast cancer. Oncotarget 9, 18985–18996 (2018).
Brahmer, J. R. et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy: American Society of Clinical Oncology clinical practice guideline. J. Clin. Oncol. 36, 1714–1768 (2018).
Nanda, R. et al. Pembrolizumab plus standard neoadjuvant therapy for high-risk breast cancer (BC): results from I-SPY 2 [abstract]. J. Clin. Oncol. 35 (Suppl. 15), 506 (2017).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
S.A. declares that she has received research funding to her institution from Merck, Genentech, Amgen, Celgene, Bristol-Myers Squibb (BMS) and Novartis and that she is a Steering committee member for IMpassion130 (uncompensated), a Global PI on Keynote-086 (uncompensated) and a consultant for BMS (uncompensated). N.D’A. declares no competing interests.
Supplementary information
Rights and permissions
About this article
Cite this article
D’Abreo, N., Adams, S. Immune-checkpoint inhibition for metastatic triple-negative breast cancer: safety first?. Nat Rev Clin Oncol 16, 399–400 (2019). https://doi.org/10.1038/s41571-019-0216-2
Published:
Issue Date:
DOI: https://doi.org/10.1038/s41571-019-0216-2
This article is cited by
-
Tumor-Targeting Extracellular Vesicles Loaded with siS100A4 for Suppressing Postoperative Breast Cancer Metastasis
Cellular and Molecular Bioengineering (2023)
-
Breast cancer cell-derived extracellular vesicles promote CD8+ T cell exhaustion via TGF-β type II receptor signaling
Nature Communications (2022)
-
Immunotherapy toxicity: identification and management
Breast Cancer Research and Treatment (2022)
-
An organoid-based screen for epigenetic inhibitors that stimulate antigen presentation and potentiate T-cell-mediated cytotoxicity
Nature Biomedical Engineering (2021)
-
Two may be better than one: PD-1/PD-L1 blockade combination approaches in metastatic breast cancer
npj Breast Cancer (2019)